Barclays Keeps a Buy Rating on Laboratory Corp (LH)


In a report released yesterday, Jack Meehan from Barclays maintained a Buy rating on Laboratory Corp (LH), with a price target of $176. The company’s shares closed yesterday at $152.61.

According to TipRanks.com, Meehan is a 4-star analyst with an average return of 6.9% and a 62.1% success rate. Meehan covers the Healthcare sector, focusing on stocks such as Bio-Rad Laboratories, PRA Health Sciences, and IQVIA Holdings Inc.

Laboratory Corp has an analyst consensus of Moderate Buy, with a price target consensus of $172.30, a 12.9% upside from current levels. In a report issued on April 2, Jefferies also upgraded the stock to Buy with a $190 price target.

See today’s analyst top recommended stocks >>

Laboratory Corp’s market cap is currently $15.09B and has a P/E ratio of 17.73. The company has a Price to Book ratio of 2.17.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Laboratory Corp. of America Holdings is a clinical laboratory company, which engages in the provision of clinical laboratory and end-to-end drug development services. It operates through the LabCorp Diagnostics and Covance Drug Development segments. The LabCorp Diagnostics segment includes core testing as well as genomic and esoteric testing.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts